Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc AGNPF


Primary Symbol: C.AGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus

GlobeNewswire March 6, 2020

Algernon Pharmaceuticals to be Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

GlobeNewswire February 26, 2020

Algernon Pharmaceuticals Announces Increase and Closing of CDN$1.55M Private Placement

GlobeNewswire February 21, 2020

Algernon Pharmaceuticals Announces Private Placement

GlobeNewswire February 13, 2020

Algernon Pharmaceuticals Appoints Professor of Respiratory Medicine Dr. Jacky Smith to Its Medical and Scientific Advisory Board

GlobeNewswire February 7, 2020

Algernon Pharmaceuticals Appoints Novotech as CRO for First Phase 2 Trial and Announces Novotech's $220K Equity Investment

GlobeNewswire January 17, 2020

Algernon Pharmaceuticals Announces OTC Trading Symbol Change to AGNPF

GlobeNewswire December 30, 2019

Algernon Pharmaceuticals Appoints Leading Respirologist Dr. Martin Kolb to Its Medical and Scientific Advisory Board

GlobeNewswire December 16, 2019

Algernon Pharmaceuticals to Present at 12th Annual LD Micro Main Event Conference on Wednesday December 11, 2019

GlobeNewswire December 10, 2019

Algernon Pharmaceuticals' NP-120 (Ifenprodil) Outperforms Merck's Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110%

GlobeNewswire December 5, 2019

Algernon Pharmaceuticals Provides Update on its Planned Phase II Clinical Trial

GlobeNewswire November 25, 2019

Algernon Announces Closing of $2.07 Million Prospectus Offering of Units

GlobeNewswire November 1, 2019

IIROC Trade Resumption - AGN

Canada NewsWire October 25, 2019

Algernon Announces Pricing and Filing of Amended and Restated Prospectus

GlobeNewswire October 25, 2019

IIROC Trading Halt - AGN

Canada NewsWire October 25, 2019

Algernon Files Final Short Form Prospectus

Stockhouse Editorial October 2, 2019

Algernon Pharmaceuticals Announces Filing of a Final Short Form Prospectus

GlobeNewswire October 2, 2019

Algernon Announces Prospectus Offering Pricing

Stockhouse Editorial September 6, 2019

Algernon Announces Pricing of Prospectus Offering

GlobeNewswire September 6, 2019

Algernon Pharmaceuticals Announces Emoxypine (NP-178), a Top Selling Drug in Russia, as its Lead Drug for Inflammatory Bowel Disease

GlobeNewswire August 2, 2019